Targeting lung cancer through inhibition of checkpoint kinases

Inhibitors of checkpoint kinases ATR, Chk1, and Wee1 are currently being tested in preclinical and clinical trials. Here, we review the basic principles behind the use of such inhibitors as anticancer agents, and particularly discuss their potential for treatment of lung cancer. As lung cancer is on...

Descripción completa

Detalles Bibliográficos
Autores principales: Syljuåsen, Randi G., Hasvold, Grete, Hauge, Sissel, Helland, Åslaug
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2015
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4343027/
https://www.ncbi.nlm.nih.gov/pubmed/25774168
http://dx.doi.org/10.3389/fgene.2015.00070

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4343027/
https://www.ncbi.nlm.nih.gov/pubmed/25774168
http://dx.doi.org/10.3389/fgene.2015.00070

Ejemplares similares